Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery.

Artificial intelligence has moved from pilot projects to a central role in many life sciences strategies. What began as a set ...

Funding and clinical trial-based barriers must be addressed to ensure success on the path to developing a DMT for Parkinson’s.

AlphaFold, a transformative AI-driven tool developed by DeepMind, has revolutionized the field of structural biology by accurately predicting protein structures. This breakthrough holds significant ...

Find out how self-driving labs utilise data-driven approaches to enhance drug discovery efficiency and innovation.

The Mystra platform, developed over 10 years, offers biopharma partners proven analytical power to turn months of R&D into minutes, dramatically increasing the availability of quality genetic insights ...

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, today announced a new contract valued at up to £617,000 with a top-five pharmaceutical company.

The Mark Foundation for Cancer Research today announced four recipients of the 2026 Drug Discovery Awards, a program designed to bridge the gap between academic discovery and clinical application.

Neuroinflammation drives the progression of neurodegenerative disorders like Alzheimer's, Parkinson's, and multiple sclerosis ...